Pedro C A Reis, Vinicius Bittar, Giulia Almirón, Ana Júlia Schramm, João Pedro Oliveira, Renato Cagnacci, Marcos P G Camandaroba
PURPOSE: Laparoscopic pancreatoduodenectomy (LPD) has emerged as an alternative to open technique in treating periampullary tumors. However, the safety and efficacy of LPD compared to open pancreatoduodenectomy (OPD) remain unclear. Thus, we conducted an updated meta-analysis to evaluate the efficacy and safety of LPD versus OPD in patients with periampullary tumors, with a particular focus on the pancreatic ductal adenocarcinoma patient subgroup. METHODS: According to PRISMA guidelines, we searched PubMed, Embase, and Cochrane Library in December 2023 for randomized controlled trials (RCTs) that directly compare LPD versus OPD in patients with periampullary tumors...
July 19, 2024: Journal of Gastrointestinal Cancer
Vanita Noronha, Anbarasan Sekar, Akhil Rajendra, Smruti Mokal, Vijay Patil, Nandini Menon, Sunil Chopade, Ajay Kumar Singh, Rajiv Kumar Kaushal, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Rajesh Dikshit, Shripad Banavali, Kumar Prabhash, Rajendra Badwe
No abstract text is available yet for this article.
July 17, 2024: Journal of Gastrointestinal Cancer
Tahseen Bilal Rather, Ishrat Parveiz, Gowhar Rashid, Kulsum Akhtar, Syed Mudassar, Rauf A Wani, Syed Besina, Rather Izhar Ul Haq
PURPOSE: Glioma-associated oncogene homolog-1 (GLI1) is amplified in human glioblastoma, and there is growing evidence suggesting its significant role in tumor development and metastasis. Our aim was to investigate the role of the GLI-1 gene in the progression of colorectal cancer (CRC) and its correlation with various clinicopathological features. Additionally, we examined the impact of the GLI-1 gene and other factors on the prognosis of CRC. METHODS: We analyzed a total of 98 confirmed CRC cases and adjacent normal tissue controls...
July 17, 2024: Journal of Gastrointestinal Cancer
Vahid Moazed, Daryoush Yousofi Zadeh, Amineh Jalali, Fatemeh Yahyazadeh Gooki, Zahra Karbakhsh Ravari
BACKGROUND: The escalating incidence of cancer and the concurrent rise in mental health issues necessitate investigation into the potential for psychological factors to impede timely and effective treatment. This study examines the association between defense mechanism styles and disease progression, specifically focusing on clinical staging, in patients diagnosed with gastrointestinal (GI) cancer. METHODS: Employing a descriptive correlational design, the study recruited 205 patients with GI cancer admitted to Javad Al-Aeme Hospital in Kerman, Iran, during the year 2022...
July 16, 2024: Journal of Gastrointestinal Cancer
Yuko Murashima, Shun Yamamoto, Toshiharu Hirose, Toru Kadono, Go Ikeda, Akihiro Ohara, Mai Itoyama, Kazuki Yokoyama, Yoshitaka Honma, Koshiro Ishiyama, Jyunya Oguma, Hiroyuki Daiko, Ken Kato
BACKGROUND: Nivolumab monotherapy is the standard second-line treatment for advanced esophageal squamous cell carcinoma (ESCC) after failure of platinum-based chemotherapy without anti-PD-1 antibody. Fixed dosing with 240 mg every 2 weeks was approved initially, followed by fixed dosing with 480 mg every 4 weeks based on pharmacokinetics data. However, information on the comparative efficacy and safety of the two doses remains limited. METHODS: We compared progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and the incidence of adverse events (AEs) between the two doses in 117 patients who received second-line (n = 85) or later-line (n = 32) nivolumab monotherapy at our institution between January 2016 and December 2021...
July 15, 2024: Journal of Gastrointestinal Cancer
Rosmawati Mohamed, Wendy Wang, Tawesak Tanwandee, Irsan Hasan, Cam Phuong Pham, Young-Suk Lim, Sheng-Nan Lu, Murallitharan Munisamy, Thi Thanh Huong Tran, Evy Ratnawati, Wattana Sukeepaisarnjaroen, Mahir Karababa, Chee-Kiat Tan
PURPOSE: In several Asian countries, hepatocellular carcinoma (HCC) is a leading cause of cancer deaths. HCC risk factors in Asia differ from those elsewhere and are changing with the treatment landscape as systemic treatment options increase. This study was conducted to gain insight from physicians and patients into HCC screening, diagnosis, and treatment strategies in Indonesia, Korea, Malaysia, Singapore, Taiwan, Thailand, and Vietnam. METHODS: Two cross-sectional, anonymized, online surveys were completed between July and December 2022 by physicians diagnosing and treating HCC (55 questions on risk factors, surveillance, diagnosis, and treatment) and patients ≥ 18 years old diagnosed with HCC (36 questions on disease knowledge, quality of life, and experiences of diagnosis and treatment)...
July 12, 2024: Journal of Gastrointestinal Cancer
Zouina Sarfraz, Azza Sarfraz, Muhammad Danyal Farooq, Musfira Khalid, Khadija Cheema, Faheem Javad, Taleah Khan, Zainab Pervaiz, Muzna Sarfraz, Ali Jaan, Subhan Sadiq, Junaid Anwar
BACKGROUND: Pancreatic cancer remains a lethal malignancy with a 5-year survival rate below 6% and about 500,000 deaths annually worldwide. Pancreatic adenocarcinoma, the most prevalent form, is commonly associated with diabetes, chronic pancreatitis, obesity, and smoking, mainly affecting individuals aged 60 to 80 years. This systematic review aims to evaluate the efficacy of immunotherapeutic approaches in the treatment of pancreatic cancer. METHODS: A systematic search was conducted to identify clinical trials (Phases I-III) assessing immunotherapy in pancreatic cancer in PubMed/Medline, CINAHL, Scopus, and Web of Science, adhering to PRISMA Statement 2020 guidelines...
July 8, 2024: Journal of Gastrointestinal Cancer
Mohamad I Itani, Bassem Farah, Margaret Wasvary, Anshu Wadehra, Tj Wilson, Brian Rutledge, Paul Naylor, Eliza W Beal, Milton Mutchnick
PURPOSE: This study tested the hypothesis that our predominately AA medical center population would demonstrate a decline in HCV-driven HCC diagnosis following the initiation of DAA treatment in 2014. Also evaluated was whether achieving an SVR prior to diagnosis of HCC improved outcomes in patients who had an HCV diagnosis after completion of treatment. METHODS: All patients with HCC seen at the Detroit Medical Center from 2009 to 2021 were identified using ICD-10 codes, and medical records were evaluated...
July 8, 2024: Journal of Gastrointestinal Cancer
Xinhong Li, Tongyu Sun, Hongyan Li, Juan Liu, Na Huang, Surong Liu
BACKGROUND: The current understanding of the prognostic significance of B cells and their role in the tumor microenvironment (TME) in esophageal carcinoma (ESCA) is limited. METHODS: We conducted a screening for B-cell-related genes through the analysis of single-cell transcriptome data. Subsequently, we developed a B-cell-related gene signature (BRGrisk) using LASSO regression analysis. Patients from The Cancer Genome Atlas cohort were divided into a training cohort and a test cohort...
July 4, 2024: Journal of Gastrointestinal Cancer
Anne-Sophie Dulac, Pietro Genova, Olivier Benoit, Cindy Neuzillet, Mostapha El Hajjam, Jean-François Emile, Frédérique Peschaud, Renato Micelli Lupinacci
PURPOSE: Treatment of retroperitoneal lymph node metastases (RPN) from colon cancer (CC) is a therapeutic challenge. Available evidence supporting a curative approach is weak and uncertainties remain concerning the extent of the dissection, the optimal timing for surgery, and the role of adjuvant radiotherapy. We report the outcomes of a curative intent strategy in a recent monocentric series of patients. METHODS: We did a retrospective review of all curative intent surgical treatment of RPN from CC performed consecutively in a French university hospital from June 2015 to April 2021...
July 2, 2024: Journal of Gastrointestinal Cancer
Huajun Zheng, Jianying Zheng, Yan Shen
BACKGROUND: Bexarotene, also recognized as Targretin, is categorized as a retinoid, a type of cancer drug. Nevertheless, the precise mechanisms of bexarotene in relation to colon cancer remain unclear. In colon cancer, SEZ6L2 was suggested as one of the biomarkers and targets. This study presents a comprehensive exploration of the role of SEZ6L2 in colon cancer. METHODS: We utilized both TCGA data and a cohort of Chinese patients. In a meticulous analysis of 478 colon cancer cases, SEZ6L2 expression levels were examined in relation to clinical characteristics, staging parameters, and treatment outcomes...
July 2, 2024: Journal of Gastrointestinal Cancer
Lokesh Agarwal, Nihar Ranjan Dash, Sujoy Pal, Kumble Seetharama Madhusudhan, Vignesh Mani
BACKGROUND: Enteral nutrition is the preferred mode of nutrition following esophagectomy. However, the preferred mode of enteral nutrition (feeding jejunostomy (FJ) vs. nasojejunal (NJ) tube) remains contentious. In this randomized controlled trial (RCT), we compared FJ with NJ tube feeding in terms of safety, feasibility, efficacy, and quality-of-life (QOL) parameters in Indian patients undergoing trans-hiatal esophagectomy (THE) for carcinoma esophagus. MATERIALS AND METHODS: This single-center, two-armed (FJ and NJ tube), non-inferiority RCT was conducted from March 2020 to January 2024...
July 2, 2024: Journal of Gastrointestinal Cancer
Hiroaki Saito, Taiga Uchiyama, Mikio Matsuoka, Toshihiko Kakiuchi, Yuichiro Eguchi, Masaharu Tsubokura, Yasuhiro Mizuno
PURPOSE: Helicobacter pylori (HP) infection, a risk factor for gastric cancer, is prevalent in Japan. Consequently, some municipalities across Japan are implementing HP screening and treatment programs for adolescents. However, little is known about parents' attitudes and awareness regarding HP screening for their children. This study aimed to elucidate parental perspectives on HP screening for their children and identify the factors influencing these attitudes. METHODS: This study focused on the parents of first-year junior high school students in Yokosuka City, Kanagawa Prefecture, where an HP screening and treatment program had been implemented for adolescents...
June 27, 2024: Journal of Gastrointestinal Cancer
V M Meyer, N Bosch, J A G van der Heijden, A J Kalkdijk-Dijkstra, J P E N Pierie, G L Beets, P M A Broens, B R Klarenbeek, H L van Westreenen
PURPOSE: The aim of this study was to assess the effect of early stoma closure on bowel function after low anterior resection (LAR) for rectal cancer. METHODS: Patients participating in the FORCE trial who underwent LAR with protective stoma were included in this study. Patients were subdivided into an early closure group (< 3 months) and late closure group (> 3 months). Endpoints of this study were the Wexner Incontinence, low anterior resection syndrome (LARS), EORTC QLQ-CR29, and fecal incontinence quality of life (FIQL) scores at 1 year...
June 26, 2024: Journal of Gastrointestinal Cancer
Yayan Fu, Jun Ren, Yue Ma, Jiajie Zhou, Wenzhe Shao, Guowei Sun, Qiannan Sun, Daorong Wang
OBJECTIVE: This study aimed to compare the clinical efficacy and quality of life of B-IIB (Billroth-II with Braun anastomosis) and B-II (Billroth-II anastomosis) in the alimentary tract reconstruction postoperative totally laparoscopic distal gastrectomy (TLDG) for gastric cancer. METHODS: From February 2016 to January 2022, 158 patients underwent totally laparoscopic distal gastrectomy and D2 lymphadenectomy in Northern Jiangsu People's Hospital, with Billroth-II with Braun anastomosis for 93 patients and Billroth-II anastomosis for 65 patients...
June 24, 2024: Journal of Gastrointestinal Cancer
Jayasree Talukdar, Abdul Malik, Kangkana Kataki, Bikash Narayan Choudhury, Munindra Narayan Baruah, Mallika Bhattacharyya, Manash Pratim Sarma, Minakshi Bhattacharjee, Mrinmoy Basak, Manash Pratim Kashyap, Sahana Bhattacharjee, Eyashin Ali, Chenole Keppen, Simanta Kalita, Manash Jyoti Kalita, Partha Pratim Das, Gautam Hazarika, Ankur Jyoti Deka, Kalpajit Dutta, Mohammad Ghaznavi Idris, Suhail Akhtar, Subhash Medhi
PURPOSE: Interleukin-8 (IL8), Interleukin-12 (IL12) and Interleukin-13 (IL13) are cytokines that play regulatory role in cancer pathogenesis. We analysed their expression profile to evaluate as molecular biomarkers of esophageal squamous cell carcinoma (ESCC) and their association with different parameters and patient survival. METHODS: Expression analysis was performed by Real time quantitative polymerase chain reaction and receiver operating characteristic (ROC) curve analysis was done...
June 23, 2024: Journal of Gastrointestinal Cancer
Samar Mahmood, Hafiz Muhammad Sameer, Arooba Ejaz, Syed Muhammad Ahsan, Urooj Mazhar, Komal Zulfiqar
PURPOSE: To examine mortality trends among non-Hispanic (NH) adults with pancreatic cancer. METHOD: CDC-WONDER database was used to extract death certificate data on pancreatic cancer-related mortality in NH adults aged ≥ 45 from 1999 to 2020. Age-adjusted mortality rates (AAMRs) per 100,000 persons and annual percent changes (APCs) were calculated and stratified by year, age, sex, race, and region. RESULTS: From 1999 to 2020, 783,772 deaths occurred among middle-aged (45-64) and older (65-85 +) NH adults...
June 18, 2024: Journal of Gastrointestinal Cancer
Patrick Maisonneuve
No abstract text is available yet for this article.
June 18, 2024: Journal of Gastrointestinal Cancer
Saneya A Pandrowala, Deeksha Kapoor, Aditya Kunte, Amit Chopde, Ameya Puranik, Indraja Devidas Dev, Rahul Parghane, Sandip Basu, Anant Ramaswamy, Vikas Ostwal, Vikram A Chaudhari, Manish S Bhandare, Shailesh V Shrikhande
INTRODUCTION: The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) has steadily increased. These tumors are considered relatively indolent even when metastatic. What determines survival outcomes in such situations is understudied. MATERIALS AND METHODS: Retrospective analysis of a prospectively maintained NET clinic database, to include patients of metastatic grade 1 GEP-NET, from January 2018 to December 2021, to assess factors affecting progression-free survival (PFS)...
June 14, 2024: Journal of Gastrointestinal Cancer
Mitsunori Ushigome, Hideaki Shimada, Tomoaki Kaneko, Yasuyuki Miura, Kimihiko Yoshida, Takayuki Suzuki, Satoru Kagami, Akiharu Kurihara, Kimihiko Funahashi
PURPOSE: This study aimed to evaluate the clinicopathological and prognostic significance of preoperative serum creatine kinase (CK) levels in colorectal cancer. METHODS: This study analyzed 1169 patients with colorectal cancer at stages 0 (n = 35), I (n = 301), II (n = 456), III (n = 339), and IV (n = 38). The CK cut-off value was 52 U/L to predict recurrence based on receiver operative characteristics curve...
June 13, 2024: Journal of Gastrointestinal Cancer
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.